摘要
目的研究腹腔注射川芎嗪对大鼠哮喘模型的防治作用及机制。方法按常用方法制作大鼠哮喘模型并分为哮喘模型组(A组),川芎嗪治疗组(L组),地塞米松治疗组(D组)和正常对照组(N组)4组,每组8只。用酶联免疫吸附实验(ELISA)检测支气管肺泡灌洗液(BALF)中白介素-4(IL-4)和白介素-5(IL-5)的浓度。用HE染色法观察气道炎症变化。用免疫组化法研究肺组织GATA-3的表达。结果L组BALF中IL-4和IL-5的浓度以及肺组织GATA-3阳性细胞的光密度值(OD值)明显低于A组BALF的IL-4和IL-5的浓度以及肺组织GATA-3阳性细胞的OD值,差异有显著性(P<0.01),与D组无显著差异(P>0.05)。结论腹腔注射川芎嗪可以抑制哮喘大鼠IL-4和IL-5的合成,其机制可能与其降低GATA-3在肺组织的表达,从而继发抑制Th2型免疫反应有关。
Objective To investigate the prevention and treatment effect of intraperitoneal ligustrazine on bronchial asthma in the SD rat asthma model and the relevant mechanism. Methods The SD rat asthma model was made with traditional method. All rats were divided into four groups： asthma group （Group A, n = 8）, ligustrazine group （Group L, n = 8）, dexarnethasone group （Group D, n =8）, and normal control group （Group N, n =8）. The level of IL-4 and IL-5 in BALF were measured by ELISA. The airway inflammation was observed with HE staining method. The expression of GATA-3 in pulmonary tissue was detected by means of immunohistoehemical staining. Results The level of IL-4 and IL-5 in BALF and the optical density of GATA-3 positive cells in pulmonary tissue in Group L were much lower than those in Group A （P〈0.01）; there was no statistically significant difference between Group L and Group D （ P〉0.05 ）. Conclusion Ligustrazine could lower the levels of IL-4 and IL-5 in the rat asthma model. The mechanism may be related to the action of ligustrazine to down-regulate GATA-3 expression in pulmonary tissue, resulting in suppression of Th2 reaction.
出处
《实用临床医药杂志》
CAS
2007年第3期36-39,44,共5页
Journal of Clinical Medicine in Practice
基金
湖北省卫生厅基金资助项目(JX1B051)
